Germany’s Boehringer Ingelheim is to make a bank of its molecules available to scientists in a bid to encourage open innovation during the COVID-19 pandemic, when many scientists are working from home.
The family-owned company has dubbed its new crowdsourcing platform opnMe, and aims to set new standards of collaboration within the scientific community.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,